Across TCGA pan-cancer cohorts, MBOAT4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MBOAT4 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MBOAT4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MBOAT4 expression acts as an unfavorable survival marker.
ACC, UCEC, and COAD are the cancer types where MBOAT4 Mutation most reproducibly stratifies survival.